Merck & Co., Inc. (NYSE:MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference January 4, 2024 ET Company Participants Peter Dannenbaum - Head, IR Rob Davis - CEO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani I suspect that people are going to be strolling in, but I don't like to penalize people who are on time, and let's try to stay on time. So let's get underway here. Welcome to what is by definition, in my opinion, the keynote presentation of this conference. We are th ...

The latest trading session saw Merck (MRK) ending at $114.77, denoting a +1.35% adjustment from its last day's close. The stock outpaced the S&P 500's daily loss of 0.8%. On the other hand, the Dow registered a loss of 0.76%, and the technology-centric Nasdaq decreased by 1.18%.Coming into today, shares of the pharmaceutical company had gained 6.6% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 3.4%.The investment community will be closely monitoring the perfo ...

Sergey Peterman Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 8 years. This is a high frequency breakout subset of the different portfolios types I regularly release has now reached 343 weeks of public selections as part of this ongoing live forward-testing research. Plus, all new long term portfolios for 2024 will be released at the end of December in a Part 2 of this article. 2023 Performance of the MDA Algorithm For 2023, ...

On Dec. 14, Moderna (MRNA -1.93%) and Merck (MRK 0.73%) jointly reported some great news for patients as well as investors: A powerful new cancer therapy is in the works, and the freshly published mid-stage clinical trial data look favorable. Now, the biotech's shares are up by 21% over the last 30 days, and they likely have much further to run over the long term.But the coronavirus vaccine developer's stock actually lost a similar proportion of its value over the last three years, and its revenue is dramat ...

JuSun It’s almost the end of the year, and is a good time to re-evaluate one’s portfolio in terms of potential winners and losers next year. With the market chasing growth stocks to nosebleed valuations, I believe better opportunities can be found to similar moat-worthy enterprises that are trading at far more reasonable valuations with a dividend kicker. This brings me to Merck (NYSE:MRK), which I last covered here in October of last year, noting the expansion of its highly profitable Keytruda drug and ...

A patient and a pharmacist talk to each other. Drazen Zigic/iStock via Getty Images It's been repeated ad nauseam, but there are no guarantees in equity investing. Even the most storied companies are susceptible to fading into the ash heap of history. At the time Lehman Brothers went bankrupt in 2008, it was in business for more than 150 years. The company established itself as the fourth-largest investment bank in the United States. High debt can only be overlooked for so long before the perfect storm brin ...

Fischerrx6 Introduction As we head into the last trading days of 2023, I wanted to cover a stock I haven't discussed before on Seeking Alpha. That company is Merck & Co. (NYSE:MRK), a drug manufacturer with a market cap of more than $270 billion. The reason why I never covered MRK is because I thought it was too boring. I was wrong. Very wrong. Over the past ten years, MRK shares have returned 215%, beating both the healthcare ETF (XLV) and the S&P 500. Data by YCharts Moreover, the stock is yielding 2. ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic ther ...

Merck & Co., Inc. (NYSE:MRK) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ET Executives Dr. Eliav Barr - Senior Vice President, Head, Global Clinical Development and CMO Peter Dannenbaum - Vice President, Investor Relations Analysts Umer Raffat - Evercore Umer Raffat Thank you. Listen, thank you guys for being here. Apologies. I’m a couple minutes behind. Pleasure to have Merck management join us. This is our last fireside of this conference, at least on my end. Dr. Eli ...

Merck & Co., Inc. (NYSE:MRK) Jefferies London Healthcare Conference November 16, 2023 5:00 AM ET Company Participants Caroline Litchfield - Chief Financial Officer Peter Dannenbaum - Head of Investor Relations Conference Call Participants Akash Tewari - Jefferies Akash Tewari All right, good morning, day three of our London Healthcare Conference. It has been a blast to see everyone here, really do appreciate it. Joining us -- and my name is Akash Tewari. I'm a pharma and biotech analyst, here at Jefferies. ...